NICE position statement on using artificial intelligence in evidence generation and reporting

In August 2024, NICE published its position statement on the use of artificial intelligence (AI) methods in the generation and reporting of evidence considered by NICE evaluation programs. The use of AI methods, from relatively well-established machine learning approaches to newer and more complex generative AI, offers several potential benefits for this process. AI methods can efficiently process and analyze large datasets to reveal patterns and relationships that may not be readily apparent to human analysts. Generative AI can create novel outputs based on what it learns from data.

The statement aims at the following:

• Outline what NICE expects when AI methods are considered or used for evidence generation and reporting;
• Indicate existing regulations, good practices, standards, and guidelines to follow when using AI methods, where appropriate;
• Support NICE committee members and external assessment groups to understand and critique the potential uses of AI methods.

NICE is aware that the use of AI methods is increasingly being explored for purposes relating to HTA, and there is likely to be increasing use or consideration in evidence generation and reporting in the near future.

This position statement provides clarity on how NICE will consider the use of AI methods in the generation and reporting of evidence to be evaluated within its guidance production programs.

NICE requires that when AI methods are used, transparency, rigor, and trust in the guidance production are maintained. Therefore, any use of AI should be done judiciously, leveraging the strengths of AI to support and enhance decision-making only when it is suitable and when it adds value. The use of AI methods should augment human involvement, not replace it.

See the full details here.

This news is just one of about 300 market access news collected by our team in the premium subscription service Market Access Monitor every week from more than 80 organizations. Access our paid service to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). Access is organized as an online Database and email alert formats. Contact us to get a free, three-month, no-obligation trial.